Eli Lilly CSO Dan Skovronsky (file photo)
#ESMO20: Eli Lilly shows off the data for its Verzenio success. Was it worth $18 billion?
The press release alone, devoid of any number except for the size of the trial, added nearly $20 billion to Eli Lilly’s market cap …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
